Meta-analysis of proportion estimates of extended-spectrum-beta-lactamase-producing <i>Enterobacteriaceae </i>in East Africa hospitals by Sonda, Tolbert et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Meta-analysis of proportion estimates of extended-spectrum-beta-lactamase-
producing Enterobacteriaceae in East Africa hospitals
Sonda, Tolbert; Kumburu, Happiness; van Zwetselaar, Marco; Alifrangis, Michael; Lund, Ole;
Kibiki, Gibson; Aarestrup, Frank M.
Published in:
Antimicrobial Resistance and Infection Control
DOI:
10.1186/s13756-016-0117-4
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Sonda, T., Kumburu, H., van Zwetselaar, M., Alifrangis, M., Lund, O., Kibiki, G., & Aarestrup, F. M. (2016). Meta-
analysis of proportion estimates of extended-spectrum-beta-lactamase-producing Enterobacteriaceae in East
Africa hospitals. Antimicrobial Resistance and Infection Control, 5, 18. https://doi.org/10.1186/s13756-016-0117-
4
Download date: 03. Feb. 2020
REVIEW Open Access
Meta-analysis of proportion estimates of
Extended-Spectrum-Beta-Lactamase-
producing Enterobacteriaceae in East Africa
hospitals
Tolbert Sonda1,2*, Happiness Kumburu1,2, Marco van Zwetselaar1, Michael Alifrangis3,4, Ole Lund6,
Gibson Kibiki1,2 and Frank M. Aarestrup5
Abstract
Background: A high proportion of Extended-Spectrum-Beta-Lactamase (ESBL) producing Enterobacteriaceae is
causing common infections in all regions of the world. The burden of antibiotic resistance due to ESBL in East
Africa is large but information is scarce and thus it is unclear how big the problem really is. To gain insight into
the magnitude and molecular epidemiology of ESBL-producing Enterobacteriaceae in East Africa a literature
search was performed in PubMed on 31 July 2015 to retrieve articles with relevant information on ESBL.
Methods and results: Meta-analysis was performed to determine overall proportion estimate of ESBL-producing
Enterobacteriaceae. A total of 4076 bacterial isolates were included in the analysis. The overall pooled proportion
of ESBL-producing Enterobacteriaceae among included surveys done in East African hospitals was found to be 0.
42 (95 % CI: 0.34–0.50). Heterogeneity (I2) between countries’ proportions in ESBL was significantly high (96.95 %
and p < 0.001). The frequently detected genes encoding ESBL were CTX-M, TEM, SHV and OXA while the most
infrequent reported genes were KPC and NDM.
Conclusion: The available studies show a very wide variation in resistance due to ESBL between countries. This
highlights a need for active surveillance systems which can help understand the actual epidemiology of ESBL, aid
in formulating national or regional guidelines for proper screening of ESBL, and support developing standardized
approaches for managing patients colonized with ESBL.
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Background
The production of beta-lactamases is the most common
mechanism for bacteria to acquire resistance to broad-
spectrum beta-lactam antibiotics. These hydrolytic en-
zymes are encoded by various gene variants. TEM,
named after Temoneira, is one of the first enzymes
identified in Europe in the 1960s in Escherichia coli [1].
Since then, several other enzymes like CTX, SHV, OXA
have been reported in different parts of the world [2–8].
Extended-Spectrum-Beta-Lactamase (ESBL) producing
Enterobacteriaceae can be defined as those producing β-
lactamases capable of conferring bacterial resistance to
the penicillins, first-, second-, and third-generation
cephalosporins, and aztreonam (but not the cephamycins
or carbapenems) by hydrolysis of these antibiotics, and
which are inhibited by β-lactamase inhibitors such as cla-
vulanic acid [9].
The proportion of ESBL-producing bacteria causing
common infections in all regions of the world is high,
making antibiotic resistance due to ESBL being a major
global public health problem [10]. Patients infected with
ESBL not only have an increased risk of treatment failure,
sometimes resulting in death, but also require more
health-care resources. ESBL bacterial infections are
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becoming challenging because physicians run out of
drug options. Although there might be differences in
magnitude depending on region or country, ESBLs used
to be considered primarily nosocomial. Currently they
can be frequently found in both hospitals and communities,
though magnitudes reported in community-based surveys
are generally lower [4, 6–8, 11–13]. Several risk factors have
been documented to be associated with ESBL acquisition,
including: previous hospitalisation, previous use of antibi-
otics such as third generation cephalosporins, hospital over-
crowding, bed sharing when hospitalised, and international
travel [3, 14–19].
Due to regional differences in the ESBL proportion
and distribution, therapeutic decisions should be based
on local guidelines derived from local epidemiological
data [20]. In resource-rich countries many surveillance
systems have been set up to estimate the burden of bacter-
ial infections including ESBL and to determine risk factors
for acquisition of ESBL bacteria as well as the clinical out-
comes associated with their infection [10, 21–23]. In East
Africa however, only scarce and scattered information is
available on ESBL epidemiology and risk factors associated
with ESBL bacterial infection. When available, the data
mostly originates from hospital-based studies [7, 24–28].
To gain a better insight in the proportion estimates and
molecular epidemiology of ESBL-producing Enterobacteria-
ceae in East Africa, we retrieved available peer-reviewed
articles and collated the information in this review article.
The PRISMA statement was used to guide the meta-
analysis [29]; the PRISMA checklist is available as sup-
plemental material (Additional file 1).
Materials and methods
Literature search and selection
We defined the East African region as the countries
forming the East African Community (Burundi, Kenya,
Rwanda, Tanzania and Uganda), with the addition of
Ethiopia, based on the UN geographical regions defin-
ition. A PubMed search was performed on 31 July 2015
using the search query “(Burundi OR Kenya OR Rwanda
OR Tanzania OR Uganda OR Ethiopia) AND (ESBL OR
extended-spectrum-beta-lactamase”. A total of 29 poten-
tial articles were found. Articles studying non-human
subjects, review articles, and articles describing isolates
from outside the six countries mentioned above were ex-
cluded. A total of 24 articles were included (Fig. 1).
Data extraction and analysis
For data consistency, two people extracted data inde-
pendently from each article. Whenever there was dis-
cordance in the data extracted, consensus was reached
by double-checking the article. Data extracted included:
name of first authors, year of study (or publication if
year of study was not documented), department, target
population, isolate source and common species isolated.
Other data extracted were the methods used to test for
ESBL, the number of Enterobacteriaceae analysed, the
number of Enterobacteriaceae positive for ESBL, the
gene variants encoding for ESBL, and risk factors for
ESBL bacterial infection.
Stata version 13.1 (College Station, Texas 77845 USA)
was used to perform meta-analysis of the proportion of
ESBL-producing Enterobacteriaceae as described by Nyaga
et al. [30]. In the analysis, a random-effects meta-analysis
model was used to calculate the pooled (weighted) propor-
tion of ESBL and the I2 statistic (measure of inconsistency).
The I2 statistic expresses the percentage of total variation
across studies due to heterogeneity. A value of 0 % shows
no observed heterogeneity, increasing values indicate
increasing heterogeneity.
Results
Distribution of articles describing ESBL in East Africa
The 24 articles reviewed were from cross-sectional
hospital-based studies. 4 (16.7 %) were from Ethiopia, 4
(16.7 %) were from Kenya, 12 (50 %) were from Tanzania,
3 (12.5 %) were from Uganda, and 1 (4.2 %) was from
Rwanda. No articles were found for Burundi. 18 (75 %) of
reviewed articles included patients attending in-patient
and out-patient departments, 4 (16.7 %) included patients
attending in-patient departments only, and 2 (8.3 %) in-
cluded patients attending out-patient departments only.
20 (83.3 %) of the reviewed articles studied E. coli plus
other species while 19 (79.2 %) studied K. pneumoniae
plus other species.
One (4.2 %) article (from Rwanda) investigated the risk
factors for infection with ESBL-producing Enterobacteria-
ceae. In this article, previous use of cephalosporins, cipro-
floxacin and hospitalisation were found to be significant
risk factors for ESBL bacterial infection.
Laboratory methods used to estimate the proportion of
ESBL
Sixteen (66.7 %) of the articles reviewed used Double
Disk Synergy Test (DDST) alone; 2 (8.3 %) articles used
PCR-sequencing alone while 6 (25 %) articles used both
DDST and PCR-sequencing methods to estimate ESBL
proportions.
Proportion estimates of ESBL in East Africa
Based on the available data (Fig. 2), East Africa’s overall
pooled proportion of ESBL-producing Enterobacteriaceae
was 0.42 (95 % CI: 0.34–0.50). Overall heterogeneity was
significant (I2 95.95 %, p < 0.001). The pooled proportion
of ESBL-producing Enterobacteriaceae in Ethiopia was
0.30 (95 % CI: 0.21–0.38), I2 was 67.98 % and p = 0.02.
The pooled proportion of ESBL-producing Enterobacteri-
aceae in Kenya was 0.47 (95 % CI: 0.23–0.71); I2 was
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98.82 % and p < 0.001. The pooled proportion of ESBL-
producing Enterobacteriaceae in Tanzania was 0.39 (95 %
CI: 0.30–0.48); I2 was 93.16 % and p < 0.001. The pooled
proportion of ESBL-producing Enterobacteriaceae in
Uganda was 0.62 (95 % CI: 0.38–0.87); I2 was 97.83 %
and p < 0.001.
The intra-country heterogeneity is reflected in the
range of the estimates of the ESBL proportion. In Tanzania,
the median (range) ESBL proportion estimate was 38.8 %
(14.2–75.9). In Kenya the median ESBL proportion was
45.8 % (13.1–88.3). Ethiopia recorded median ESBL propor-
tion of 30.9 % (21.9–40.4). In Uganda the recorded median
ESBL proportion was 61.7 % (43.8–81.4). The single article
for Rwanda reported a 38.3 % ESBL proportion (Fig. 3).
Molecular epidemiology of ESBL in East Africa
Out of 24 reviewed articles, 8 (33.3 %) of which, 4 (50 %)
from Tanzania, 3 (37.5 %) from Kenya and 1 (12.5 %) from
Uganda had data on ESBL-encoding genes. The predomin-
ant ESBL-encoding genes reported were CTX-M, TEM and
SHV. Five articles provided proportion estimates for these
genes (Table 1). One article reported no quantitative data
but identified the same three genes [12]. One article identi-
fied CTX-M-15, CMY-2 and AmpC [31], One article re-
ported the multi resistant and rarer genes VIM (12.3 %),
OXA-48 (4.9 %), KPC (3.5 %) and NDM (3.1 %) genes [42].
Discussion
The scarcity of studies available from the East African re-
gion warrants caution in drawing conclusions. Little infor-
mation overall is available, with no studies on Burundi
and only one on Rwanda. However, this review finds high
proportion estimates of ESBL-producing Enterobacteria-
ceae across hospitals in the East African region.
The overall pooled ESBL proportion estimate for East
African hospitals (42 %) is close to estimates for Ghana
(49 %), Cameroon (54 %), Gabon (45 %) and Morocco
(43 %) [18, 32–34]. This estimate is also close to data
reported for China, where a nationwide survey that in-
cluded 30 hospitals reported over 46 % resistance due to
ESBL [35]. However the East African proportion is con-
siderably higher than averages reported for resource-rich
countries. For instance, the average ESBL proportion
estimates reported in a nationwide hospital survey in
Germany for 2012 were in the 10 to 15 % range [36]. In
2012, a study for nine US census regions reported ESBL
proportion estimates in the 4 to 12 % range [37], while a
9-year survey in Japan recorded a proportion estimate of
6.3 % in 2003 increasing to 10–20 % in 2011 [38]. It
should be noted that this study focused on community-
acquired infections whereas the other studies concerned
nosocomial-infections.
In this review, inter-country and inter-study results
show a wide and statistically significant degree of variation
Fig. 1 Flow diagram summarising the process of literature search and selection
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in proportion estimates (p < 0.05 in all cases). There are
several possible factors that may account for the variations
seen in this review. The first factor is the difference in sen-
sitivity and specificity between methods used in estimating
proportions. Some studies reviewed estimated ESBL pro-
portions using purely phenotypic methods, while others
used both phenotypic and molecular-based methods. The
study done in Uganda shows the proportion estimate
using genotypic methods being higher (44 %) than when
the same isolates were screened for ESBL using pheno-
typic methods (18 %) [39].
A second factor contributing to the variation in pro-
portion estimates is type of wards or units, site of infec-
tion, type of specimen collected and whether patients
Fig. 2 Proportion estimates of ESBL-producing Enterobacteriaceae in East African hospitals. Midpoint of each horizontal line segment shows the
proportion estimate of ESBL in each study. Rhombic mark shows the pooled proportion from all studies included
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were attending out-patient or in-patient departments.
Hospitalised patients especially in intensive care units
are generally at a higher risk of acquiring nosocomial
infections, which are likely to be ESBL-producers than
patients attending out-patient departments [6, 7, 40–42].
The Rwanda study [15] reports ESBL proportions of
38 % and 5.9 % among inpatients and outpatients re-
spectively, within a single hospital. Similar findings have
been documented in Cameroon where ESBL proportions
were 23.1 and 6.7 % among outpatients and healthy vol-
unteers respectively [16].
Many reports have documented the difference in ESBL
proportion estimates between hospitals and congested
centers (such as orphanages) versus community-based
surveys [15, 16, 43–46]. The lack of any estimates for
community-based ESBL carriage in East Africa under-
scores an urgent need for surveillance in the region. In-
fection control in hospitals including hand hygiene and
rational antibiotic use can be effective measures to stop
further spread of the ESBL-producing Enterobacteria-
ceae in both hospitals and communities.
We noted that few (33.3 %) articles investigated different
genes encoding ESBL [6, 12, 24, 31, 39, 47–49]. The most
common gene variants in these articles are those encoding
CTX, TEM and SHV. However one study in Tanzania re-
ported occurrence of genes such as NDM that confer re-
sistance to Carbapenem [47]. With such little information
in hand, it is difficult to devise focused and effective inter-
ventions for containing resistance. Data from other parts
of the world, notably from resource-rich countries, might
not be generalisable to African settings.
Risk factors associated with resistance due to ESBL are
key for planning the optimal approach to managing the
problem. Of the reviewed articles only the one study
done in Rwanda investigated these factors. It was concluded
that previous use of ciprofloxacin, third-generation ceph-
alosporin and being an inpatient or hospitalised are risk fac-
tors for ESBL carriage [15]. Similarly, several studies done
in other sub-Saharan African countries have documented
the previous use of antibiotics (ciprofloxacin), previous hos-
pitalisation, overcrowding in hospitals, and bed sharing to
be associated with ESBL colonisation [14, 16, 17]. These
findings are consistent with several studies done outside of
Africa [50–58].
In African settings previous antibiotics use is not en-
tirely dependent on previous hospitalisation. Over-the-
counter sale of drugs or self-medication, consumption
of counterfeit drugs, improper dosage and non-adherence
are very common. These practices unnecessarily fuel the
process of positive selection for many types of antibiotic
resistance. The majority of sub-Saharan hospitals lack an-
tibiotics resistance monitoring systems, proper antibiotic
usage guidelines and proper hospital premises disinfection
guidelines. If we do not put strong pragmatic measures in
place our hospitals may soon turn into hotspots not only
for ESBL-producing Enterobacteriaceae, but also for many
other types of resistant microorganisms.
When interpreting the data compiled in this review, a
number of limitations must be taken into account. All
studies took place in university teaching or referral hospi-
tals, which will have a different case-mix from peripheral
health centres, and will generally be located in urban areas.
Another source of bias is the fact that no study included
community-based findings. As in any meta-analysis, the
pooled proportions across studies must be interpreted
with care, as protocols for observational studies are not
Fig. 3 Proportion estimates of ESBL-producing Enterobacteriaceae East African hospitals with 95 % Confidence Intervals by country. Open circles
show the proportion estimate of ESBL in each study. Solid circles show the pooled proportion from all studies included
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Table 1 Distribution of articles reviewed on resistance due to ESBL in East Africa hospitals and common gene variants encoding for ESBL
Country Year Hospital Department Population Specimen Method Species Isolates
(N)
ESBL
(%)
ESBL-Genes
Ethiopia [48] 2004 Regional aBoth Children, adults Urine, pus, sputum bDDST K. pneumoniae 57 42 cND
Ethiopia [49] 2014 University Both Children, adults Urine DDST K. pneumoniae, E. coli 183 22 ND
Ethiopia [50] 2006 University Out-patient Children Blood, stool DDST Salmonella spp 81 27 ND
Ethiopia [51] 2012 University Both Children, adults Urine, pus, wound,
sputum, stool
DDST E. coli 67 36 ND
Kenya [38] 2010 Not Stated Both Children, adults Urine, stool, blood DDST, PCR-Sequencing E. coli 912 27 CTX-M (78 %), SHV (3–5 %),
TEM (16 %)
Kenya [30] 2007 University Both Children, adults Urine PCR-Sequencing E. coli 17 71 CTX-M-15 type ESBLs and
CMY-2 AmpC
Kenya [52] 2008 University Both Children, adults Blood DDST K. pneumoniae, E. coli 359 14 ND
Kenya [37] 2012 University Both Children, adults Urine, pus, sputum,
stool
DDST, PCR-Sequencing K. pneumoniae, E. coli 52 89 CTX-M (88.5 %), blaSHV (25 %),
TEM (34.6 %)
Rwanda [14] 2009 University Both Children, adults Urine DDST K. pneumoniae, E. coli,
others
196 38 ND
Tanzania [11] 2001 University In-patients Children Blood DDST, PCR-Sequencing K. pneumoniae, E. coli 125 15 CTX-M, SHV, TEM
Tanzania [24] 2009 University In-patients Children, adults Urine, pus, wound,
blood
DDST, PCR-Sequencing K. pneumoniae 183 50 CTX-M-15 (76 %), TEM-104 (19 %),
TEM-176 (2 %), SHV-11 (3.2 %)
Tanzania [6] 2003 University In-patients Children, adults Urine, wound, blood DDST, PCR-Sequencing E. coli, Enterobacter spp,
others
39 28 TEM (55 %), SHV (64 %),
CTX-M (45.4 %)
Tanzania [7] 2010 University Both Children, adults Urine DDST K. pneumoniae, E. coli 270 45 ND
Tanzania [53] 2009 University Both Children, adults Urine, pus, wound,
blood
DDST K. pneumoniae,
Escherichia coli,
Acinetobacter spp
377 29 ND
Tanzania [54] 2013 University In-patients Women, neonates Rectal swabs DDST K. pneumoniae, E. coli,
Enterobacter spp
113 15 ND
Tanzania [55] 2013 University Both Children Urine DDST K. pneumoniae, E. coli,
others
84 44 ND
Tanzania [56] 2012 University Both Children, adults Pus DDST K. pneumoniae, E. coli,
others
29 79 ND
Tanzania [36] 2007 University Both Children, adults Urine, pus, blood dPCR-Sequencing K. pneumoniae, E. coli, P.
aeruginosa, others
227 35 VIM (12.3 %), OXA-48 (4.9 %),
KPC (3.5 %), NDM (3.1 %)
Tanzania [57] 2012 University Both Children, adults Wound DDST Pseudomonas spp,
Proteus spp, K.
pneumoniae,
E. coli
117 35 ND
Tanzania [58] 2011 University Both Children, adults Wound DDST K. pneumoniae, E. coli,
others
24 71 ND
Tanzania [59] 2009 University Both Children Blood DDST 72 49 ND
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Table 1 Distribution of articles reviewed on resistance due to ESBL in East Africa hospitals and common gene variants encoding for ESBL (Continued)
K. pneumoniae, E. coli,
others
Uganda [10] 2011 Regional Both Children, adults Wound DDST K. pneumoniae, E. coli,
others
145 81 ND
Uganda [60] 2014 Regional Both Children, adults Urine, blood, wound, CSFe DDST E. coli, K. pneumoniae, P.
mirabilis, others
115 62 ND
Uganda [31] 2012 Regional Both Children, adults Urine, pus, wound, sputum,
stool, CSF, vaginal-swabs
DDST, PCR-Sequencing K. pneumoniae, E. coli,
Salmonella spp, others
484 44 CTX-M (70 %), SHV (34 %)
and TEM (47 %)
aBoth, out-and in-patients departments
bDDST double disc synergy test
cND not determined
dPCR polymerase chain reaction
eCSF cerebrospinal fluid
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standardised across the studies included in the review.
A notable factor contributing to variation is the differ-
ent mix of in- and outpatients between the studies.
Finally, the authors acknowledge that more data on
ESBL in East Africa may be available from sources other
than those searched for this review.
Conclusion
The burden of antibiotic resistance due to ESBL is present
across East African region. Little information overall is
available, and close to none for Burundi. The available stud-
ies present proportion estimates due to ESBL with a wide
degree of variation. The scarcity of data on predictors, clin-
ical outcomes, magnitudes and gene variants encoding re-
sistance due to ESBL-producing Enterobacteriaceae calls
for active surveillance systems, which can help understand
the current epidemiology of ESBL within the region. Fur-
thermore this can aid in developing national and regional
guidelines for proper screening of ESBL as well as develop-
ing standardized approaches for managing patients colo-
nized with ESBL-producing Enterobacteriaceae.
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